Clinical trial involving selenium supplementation to counter arsenic toxicity among rural population in Bangladesh

M. Alauddin; T. Wheaton; M. Valencia; E. Stekolchik; J. E. Spallholz; P. F. La Porte; S. Ahmed; B. Chakaraborty; M. Bhattacharjee; A. B.M. Zakaria; S. Sultana; Graham N. George; Ingrid J. Pickering; Jürgen Gailer

doi:10.1201/b12522-59

Clinical trial involving selenium supplementation to counter arsenic toxicity among rural population in Bangladesh

M. Alauddin, T. Wheaton, M. Valencia, E. Stekolchik, J. E. Spallholz, P. F. La Porte, S. Ahmed, B. Chakaraborty, M. Bhattacharjee, A. B.M. Zakaria, S. Sultana, Graham N. George, Ingrid J. Pickering, Jürgen Gailer

Nutritional Sciences

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

2 Scopus citations

Abstract

In a randomized, placebo controlled, double-blind Phase III clinical trial, selenium supplements were given to patients in 14 villages in Chandpur District in Bangladesh to combat chronic arsenic poisoning resulting from drinking arsenic laced groundwater. About 413 subjects were given 200 μg sodium selenite per day as oral supplements and 408 subjects received matching placebo. Urine Arsenic (As), Selenium (Se) and Plasma Selenium (Se) were analyzed at 0, 24 and 48 weeks of supplementation. In addition, Selenoprotein Glutathione Peroxidase (GPx), Thioredoxin Reductase (TrxR) and selenoprotein P were measured in select few plasma samples at 0, 24 and 48 weeks following selenite supplementation. The trial was successfully conducted with high compliance as measured from DOTS and correct treatment assignment and dispensation as evidenced by the Se levels in plasma and urine. No consistent effect of selenite supplementation on plasma and urinary arsenic levels were observed. However, Glutathione Perxidase (GPx), Thioredoxin Reductase (TrxR) activity and selenoprotein P in plasma seem to increase with supplementation. Selenium supplementation appears to increase plasma selenium and selenoprotein levels in arsenicosis patients.

Original language	English
Title of host publication	Understanding the Geological and Medical Interface of Arsenic, As 2012 - 4th International Congress
Subtitle of host publication	Arsenic in the Environment
Publisher	Taylor and Francis - Balkema
Pages	143-147
Number of pages	5
ISBN (Print)	9780415637633
DOIs	https://doi.org/10.1201/b12522-59
State	Published - 2012
Event	4th International Congress on Arsenic in the Environment, As 2012 - Cairns, QLD, Australia Duration: Jul 22 2012 → Jul 27 2012

Publication series

Name	Understanding the Geological and Medical Interface of Arsenic, As 2012 - 4th International Congress: Arsenic in the Environment

Conference

Conference	4th International Congress on Arsenic in the Environment, As 2012
Country	Australia
City	Cairns, QLD
Period	07/22/12 → 07/27/12

Access to Document

10.1201/b12522-59

Link to publication in Scopus

Fingerprint Dive into the research topics of 'Clinical trial involving selenium supplementation to counter arsenic toxicity among rural population in Bangladesh'. Together they form a unique fingerprint.

Cite this

Alauddin, M., Wheaton, T., Valencia, M., Stekolchik, E., Spallholz, J. E., La Porte, P. F., Ahmed, S., Chakaraborty, B., Bhattacharjee, M., Zakaria, A. B. M., Sultana, S., George, G. N., Pickering, I. J., & Gailer, J. (2012). Clinical trial involving selenium supplementation to counter arsenic toxicity among rural population in Bangladesh. In Understanding the Geological and Medical Interface of Arsenic, As 2012 - 4th International Congress: Arsenic in the Environment (pp. 143-147). (Understanding the Geological and Medical Interface of Arsenic, As 2012 - 4th International Congress: Arsenic in the Environment). Taylor and Francis - Balkema. https://doi.org/10.1201/b12522-59

Alauddin, M. ; Wheaton, T. ; Valencia, M. ; Stekolchik, E. ; Spallholz, J. E. ; La Porte, P. F. ; Ahmed, S. ; Chakaraborty, B. ; Bhattacharjee, M. ; Zakaria, A. B.M. ; Sultana, S. ; George, Graham N. ; Pickering, Ingrid J. ; Gailer, Jürgen. / Clinical trial involving selenium supplementation to counter arsenic toxicity among rural population in Bangladesh. Understanding the Geological and Medical Interface of Arsenic, As 2012 - 4th International Congress: Arsenic in the Environment. Taylor and Francis - Balkema, 2012. pp. 143-147 (Understanding the Geological and Medical Interface of Arsenic, As 2012 - 4th International Congress: Arsenic in the Environment).

@inproceedings{2e6a70c3951042f98b69041d0c66fc5e,

title = "Clinical trial involving selenium supplementation to counter arsenic toxicity among rural population in Bangladesh",

abstract = "In a randomized, placebo controlled, double-blind Phase III clinical trial, selenium supplements were given to patients in 14 villages in Chandpur District in Bangladesh to combat chronic arsenic poisoning resulting from drinking arsenic laced groundwater. About 413 subjects were given 200 μg sodium selenite per day as oral supplements and 408 subjects received matching placebo. Urine Arsenic (As), Selenium (Se) and Plasma Selenium (Se) were analyzed at 0, 24 and 48 weeks of supplementation. In addition, Selenoprotein Glutathione Peroxidase (GPx), Thioredoxin Reductase (TrxR) and selenoprotein P were measured in select few plasma samples at 0, 24 and 48 weeks following selenite supplementation. The trial was successfully conducted with high compliance as measured from DOTS and correct treatment assignment and dispensation as evidenced by the Se levels in plasma and urine. No consistent effect of selenite supplementation on plasma and urinary arsenic levels were observed. However, Glutathione Perxidase (GPx), Thioredoxin Reductase (TrxR) activity and selenoprotein P in plasma seem to increase with supplementation. Selenium supplementation appears to increase plasma selenium and selenoprotein levels in arsenicosis patients.",

author = "M. Alauddin and T. Wheaton and M. Valencia and E. Stekolchik and Spallholz, {J. E.} and {La Porte}, {P. F.} and S. Ahmed and B. Chakaraborty and M. Bhattacharjee and Zakaria, {A. B.M.} and S. Sultana and George, {Graham N.} and Pickering, {Ingrid J.} and J{\"u}rgen Gailer",

year = "2012",

doi = "10.1201/b12522-59",

language = "English",

isbn = "9780415637633",

series = "Understanding the Geological and Medical Interface of Arsenic, As 2012 - 4th International Congress: Arsenic in the Environment",

publisher = "Taylor and Francis - Balkema",

pages = "143--147",

booktitle = "Understanding the Geological and Medical Interface of Arsenic, As 2012 - 4th International Congress",

}

Alauddin, M, Wheaton, T, Valencia, M, Stekolchik, E, Spallholz, JE, La Porte, PF, Ahmed, S, Chakaraborty, B, Bhattacharjee, M, Zakaria, ABM, Sultana, S, George, GN, Pickering, IJ & Gailer, J 2012, Clinical trial involving selenium supplementation to counter arsenic toxicity among rural population in Bangladesh. in Understanding the Geological and Medical Interface of Arsenic, As 2012 - 4th International Congress: Arsenic in the Environment. Understanding the Geological and Medical Interface of Arsenic, As 2012 - 4th International Congress: Arsenic in the Environment, Taylor and Francis - Balkema, pp. 143-147, 4th International Congress on Arsenic in the Environment, As 2012, Cairns, QLD, Australia, 07/22/12. https://doi.org/10.1201/b12522-59

Clinical trial involving selenium supplementation to counter arsenic toxicity among rural population in Bangladesh. / Alauddin, M.; Wheaton, T.; Valencia, M.; Stekolchik, E.; Spallholz, J. E.; La Porte, P. F.; Ahmed, S.; Chakaraborty, B.; Bhattacharjee, M.; Zakaria, A. B.M.; Sultana, S.; George, Graham N.; Pickering, Ingrid J.; Gailer, Jürgen.

Understanding the Geological and Medical Interface of Arsenic, As 2012 - 4th International Congress: Arsenic in the Environment. Taylor and Francis - Balkema, 2012. p. 143-147 (Understanding the Geological and Medical Interface of Arsenic, As 2012 - 4th International Congress: Arsenic in the Environment).

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

TY - GEN

T1 - Clinical trial involving selenium supplementation to counter arsenic toxicity among rural population in Bangladesh

AU - Alauddin, M.

AU - Wheaton, T.

AU - Valencia, M.

AU - Stekolchik, E.

AU - Spallholz, J. E.

AU - La Porte, P. F.

AU - Ahmed, S.

AU - Chakaraborty, B.

AU - Bhattacharjee, M.

AU - Zakaria, A. B.M.

AU - Sultana, S.

AU - George, Graham N.

AU - Pickering, Ingrid J.

AU - Gailer, Jürgen

PY - 2012

Y1 - 2012

N2 - In a randomized, placebo controlled, double-blind Phase III clinical trial, selenium supplements were given to patients in 14 villages in Chandpur District in Bangladesh to combat chronic arsenic poisoning resulting from drinking arsenic laced groundwater. About 413 subjects were given 200 μg sodium selenite per day as oral supplements and 408 subjects received matching placebo. Urine Arsenic (As), Selenium (Se) and Plasma Selenium (Se) were analyzed at 0, 24 and 48 weeks of supplementation. In addition, Selenoprotein Glutathione Peroxidase (GPx), Thioredoxin Reductase (TrxR) and selenoprotein P were measured in select few plasma samples at 0, 24 and 48 weeks following selenite supplementation. The trial was successfully conducted with high compliance as measured from DOTS and correct treatment assignment and dispensation as evidenced by the Se levels in plasma and urine. No consistent effect of selenite supplementation on plasma and urinary arsenic levels were observed. However, Glutathione Perxidase (GPx), Thioredoxin Reductase (TrxR) activity and selenoprotein P in plasma seem to increase with supplementation. Selenium supplementation appears to increase plasma selenium and selenoprotein levels in arsenicosis patients.

AB - In a randomized, placebo controlled, double-blind Phase III clinical trial, selenium supplements were given to patients in 14 villages in Chandpur District in Bangladesh to combat chronic arsenic poisoning resulting from drinking arsenic laced groundwater. About 413 subjects were given 200 μg sodium selenite per day as oral supplements and 408 subjects received matching placebo. Urine Arsenic (As), Selenium (Se) and Plasma Selenium (Se) were analyzed at 0, 24 and 48 weeks of supplementation. In addition, Selenoprotein Glutathione Peroxidase (GPx), Thioredoxin Reductase (TrxR) and selenoprotein P were measured in select few plasma samples at 0, 24 and 48 weeks following selenite supplementation. The trial was successfully conducted with high compliance as measured from DOTS and correct treatment assignment and dispensation as evidenced by the Se levels in plasma and urine. No consistent effect of selenite supplementation on plasma and urinary arsenic levels were observed. However, Glutathione Perxidase (GPx), Thioredoxin Reductase (TrxR) activity and selenoprotein P in plasma seem to increase with supplementation. Selenium supplementation appears to increase plasma selenium and selenoprotein levels in arsenicosis patients.

UR - http://www.scopus.com/inward/record.url?scp=84864879995&partnerID=8YFLogxK

U2 - 10.1201/b12522-59

DO - 10.1201/b12522-59

M3 - Conference contribution

AN - SCOPUS:84864879995

SN - 9780415637633

T3 - Understanding the Geological and Medical Interface of Arsenic, As 2012 - 4th International Congress: Arsenic in the Environment

SP - 143

EP - 147

BT - Understanding the Geological and Medical Interface of Arsenic, As 2012 - 4th International Congress

PB - Taylor and Francis - Balkema

Y2 - 22 July 2012 through 27 July 2012

ER -

Alauddin M, Wheaton T, Valencia M, Stekolchik E, Spallholz JE, La Porte PF et al. Clinical trial involving selenium supplementation to counter arsenic toxicity among rural population in Bangladesh. In Understanding the Geological and Medical Interface of Arsenic, As 2012 - 4th International Congress: Arsenic in the Environment. Taylor and Francis - Balkema. 2012. p. 143-147. (Understanding the Geological and Medical Interface of Arsenic, As 2012 - 4th International Congress: Arsenic in the Environment). https://doi.org/10.1201/b12522-59